These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 34607932

  • 1. Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer.
    Cruz-Collazo A, Ruiz-Calderon JF, Picon H, Borrero-Garcia LD, Lopez I, Castillo-Pichardo L, Del Mar Maldonado M, Duconge J, Medina JI, Bayro MJ, Hernández-O'Farrill E, Vlaar CP, Dharmawardhane S.
    Mol Cancer Ther; 2021 Dec; 20(12):2420-2432. PubMed ID: 34607932
    [Abstract] [Full Text] [Related]

  • 2. Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer.
    Humphries-Bickley T, Castillo-Pichardo L, Hernandez-O'Farrill E, Borrero-Garcia LD, Forestier-Roman I, Gerena Y, Blanco M, Rivera-Robles MJ, Rodriguez-Medina JR, Cubano LA, Vlaar CP, Dharmawardhane S.
    Mol Cancer Ther; 2017 May; 16(5):805-818. PubMed ID: 28450422
    [Abstract] [Full Text] [Related]

  • 3. RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P, Carlson JH, Jepperson T, Willis S, Leyland-Jones B, Dey N.
    Oncotarget; 2017 Jan 10; 8(2):3072-3103. PubMed ID: 27902969
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer.
    Velázquez-Vega LE, Rivera-Robles M, Sánchez-Álvarez AO, Vivas-Mejía PE, Aponte-Reyes M, Cruz-Collazo AM, Grafals-Ruiz N, Dorta-Estremera S, Hernández-O'Farrill E, Vlaar CP, Dharmawardhane S.
    Transl Oncol; 2024 Jun 10; 44():101928. PubMed ID: 38489873
    [Abstract] [Full Text] [Related]

  • 5. Characterization of Novel Derivatives of MBQ-167, an inhibitor of the GTP-binding proteins Rac/Cdc42.
    Medina JI, Cruz-Collazo A, Del Mar Maldonado M, Gascot TM, Borrero-Garcia LD, Cooke M, Kazanietz MG, O'Farril EH, Vlaar CP, Dharmawardhane S.
    Cancer Res Commun; 2022 Dec 10; 2(12):1711-1726. PubMed ID: 36861094
    [Abstract] [Full Text] [Related]

  • 6. Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models.
    Torres-Sanchez A, Rivera-Robles M, Castillo-Pichardo L, Martínez-Ferrer M, Dorta-Estremera SM, Dharmawardhane S.
    Front Oncol; 2023 Dec 10; 13():1152458. PubMed ID: 37397366
    [Abstract] [Full Text] [Related]

  • 7. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
    Xiao Y, Li Y, Tao H, Humphries B, Li A, Jiang Y, Yang C, Luo R, Wang Z.
    Cancer Lett; 2018 Oct 01; 433():199-209. PubMed ID: 29964204
    [Abstract] [Full Text] [Related]

  • 8. Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells.
    Baugher PJ, Krishnamoorthy L, Price JE, Dharmawardhane SF.
    Breast Cancer Res; 2005 Oct 01; 7(6):R965-74. PubMed ID: 16280046
    [Abstract] [Full Text] [Related]

  • 9. Novel Inhibition of Central Carbon Metabolism Pathways by Rac and CDC42 inhibitor MBQ167 and Paclitaxel.
    Cruz-Collazo AM, Katsara O, Grafals-Ruiz N, Colon Gonzalez J, Dorta-Estremera S, Carlo VP, Chorna N, Schneider RJ, Dharmawardhane S.
    Mol Cancer Ther; 2024 Nov 04; 23(11):1613-1625. PubMed ID: 39087451
    [Abstract] [Full Text] [Related]

  • 10. Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase.
    Montalvo-Ortiz BL, Castillo-Pichardo L, Hernández E, Humphries-Bickley T, De la Mota-Peynado A, Cubano LA, Vlaar CP, Dharmawardhane S.
    J Biol Chem; 2012 Apr 13; 287(16):13228-38. PubMed ID: 22383527
    [Abstract] [Full Text] [Related]

  • 11. A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice.
    Zins K, Lucas T, Reichl P, Abraham D, Aharinejad S.
    PLoS One; 2013 Apr 13; 8(9):e74924. PubMed ID: 24040362
    [Abstract] [Full Text] [Related]

  • 12. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD, Bai WQ, Zhai XT, Sun LP, Zhen YS, Li ZR, Miao QF.
    Mil Med Res; 2021 Dec 09; 8(1):63. PubMed ID: 34879870
    [Abstract] [Full Text] [Related]

  • 13. Targeting Cdc42 with the anticancer compound MBQ-167 inhibits cell polarity and growth in the budding yeast S. cerevisiae.
    Rivera-Robles MJ, Medina-Velázquez J, Asencio-Torres GM, González-Crespo S, Rymond BC, Rodríguez-Medina J, Dharmawardhane S.
    Small GTPases; 2020 Nov 09; 11(6):430-440. PubMed ID: 29969362
    [Abstract] [Full Text] [Related]

  • 14. Maspin controls mammary tumor cell migration through inhibiting Rac1 and Cdc42, but not the RhoA GTPase.
    Shi HY, Stafford LJ, Liu Z, Liu M, Zhang M.
    Cell Motil Cytoskeleton; 2007 May 09; 64(5):338-46. PubMed ID: 17301947
    [Abstract] [Full Text] [Related]

  • 15. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS.
    Breast Cancer Res; 2017 Jun 30; 19(1):74. PubMed ID: 28666462
    [Abstract] [Full Text] [Related]

  • 16. Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK.
    Wu Q, Ma X, Jin Z, Ni R, Pan Y, Yang G.
    J Ethnopharmacol; 2023 Oct 28; 315():116644. PubMed ID: 37196814
    [Abstract] [Full Text] [Related]

  • 17. The Rac inhibitor HV-107 as a potential therapeutic for metastatic breast cancer.
    Crespo GV, Ortiz J, O'Farrill EH, Vlaar CP, Inyushin M, Kucheryavykh Y, Kucheryavykh L.
    Mol Med; 2023 Jun 14; 29(1):75. PubMed ID: 37316799
    [Abstract] [Full Text] [Related]

  • 18. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis.
    Guo Y, Kenney SR, Muller CY, Adams S, Rutledge T, Romero E, Murray-Krezan C, Prekeris R, Sklar LA, Hudson LG, Wandinger-Ness A.
    Mol Cancer Ther; 2015 Oct 14; 14(10):2215-27. PubMed ID: 26206334
    [Abstract] [Full Text] [Related]

  • 19. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT.
    Breast Cancer Res Treat; 2019 Jun 14; 175(2):339-351. PubMed ID: 30826934
    [Abstract] [Full Text] [Related]

  • 20. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis.
    Humphries B, Wang Z, Oom AL, Fisher T, Tan D, Cui Y, Jiang Y, Yang C.
    Carcinogenesis; 2014 Oct 14; 35(10):2254-63. PubMed ID: 24925028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.